AOD-9604 vs SS-31 (Elamipretide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.
Full details →SS-31 (Elamipretide)
SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.
Full details →Side-by-Side Comparison
| Aspect | AOD-9604 | SS-31 (Elamipretide) |
|---|---|---|
| Dose Range | 300 mcg–500 mcg | 20 mg–40 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 12–24 weeks | 4–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors. | Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency. |
| Typical Dosage | Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg. | Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily. |
| Administration | Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects. | Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions. |
| Side Effects | Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH. | Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache. |
| Best For |
Key Differences
Unique to AOD-9604:
Unique to SS-31 (Elamipretide):
Key Studies
AOD-9604
- AOD-9604 does not influence the WADA hGH isoform immunoassay.
Drug testing and analysis, 2013
- AOD-9604 Metabolic.
Current opinion in investigational drugs (London, England : 2000), 2004
SS-31 (Elamipretide)
- Elamipretide: First Approval.
Drugs, 2026
- Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.
Circulation. Heart failure, 2026
- Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.
Neurochemical research, 2026
Ready to Learn More?
Looking for trusted sources?